The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
ApexOnco Front Page
Recent articles
Solstice Oncology acquires porustobart from Harbour Biomed.
Studies presented at ASH show this to be true only up to a point.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
Pfizer reveals the discontinuation of PF-08046044.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The company will try to get the Komzifti QTc prolongation warning removed.
